Nationwide coverage and cost-sharing for PCSK9 inhibitors among Medicare Part D plans

JAMA Cardiology

Volumn 2, Issue 10, 2017, Pages 1164-1166

  Kazi, Dhruv S ^a   Lu, Christine Y ^b,c   Lin, Grace A ^a   DeJong, Colette ^a   Dudley, R Adams ^a   Chen, Randi ^d   Tseng, Chien Wen ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD PILGRIM HEALTH CARE INSTITUTE   (United States)

^d PACIFIC HEALTH RESEARCH AND EDUCATION INSTITUTE   (United States)

^e UNIVERSITY OF HAWAII   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALIROCUMAB; ATORVASTATIN; EVOLOCUMAB; HYPOCHOLESTEROLEMIC AGENT; MONOCLONAL ANTIBODY; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9;

ARTICLE; CEREBROVASCULAR ACCIDENT; DRUG COST; FAMILIAL HYPERCHOLESTEROLEMIA; HEART INFARCTION; HUMAN; INFORMED CONSENT; ISCHEMIC HEART DISEASE; MEDICARE; MEDICATION COMPLIANCE; PRIORITY JOURNAL; RISK REDUCTION; ADULT; ANTAGONISTS AND INHIBITORS; ATHEROSCLEROSIS; COST; ECONOMICS; HEALTH CARE COST; HYPERCHOLESTEROLEMIA; UNITED STATES;

ADULT; ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; COST SHARING; HEALTH EXPENDITURES; HUMANS; HYPERCHOLESTEROLEMIA; MEDICARE; PROPROTEIN CONVERTASE 9; UNITED STATES; UNIVERSAL HEALTH INSURANCE;

EID: 85032493707     PISSN: 23806583     EISSN: 23806591     Source Type: Journal    
DOI: 10.1001/jamacardio.2017.3051     Document Type: Article

References (6)

1. Kazi DS, Moran AE, Coxson PG, et al. Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. JAMA. 2016;316(7):743-753. doi:10.1001 /jama.2016.11004
2. Sabatine MS, Giugliano RP, Keech AC, et al; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713-1722. doi:10.1056 /NEJMoa1615664
3. Williams J, Steers WN, Ettner SL, Mangione CM, Duru OK. Cost-related nonadherence by medication type among Medicare Part D beneficiaries with diabetes. Med Care. 2013;51(2):193-198.
4. Centers for Medicare and Medicaid Services. Chronic conditions. https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends -and-Reports/Chronic-Conditions/CC_Main.html. Accessed May 2, 2017.
5. The Medicare Part D Prescription Drug Benefit. Kaiser Family Foundation. http://kff.org/medicare/fact-sheet/the-medicare-prescription-drug-benefit-fact-sheet/. Published September 26, 2016. Accessed May 2, 2017.
6. Schulman KA, Balu S, Reed SD. Specialty pharmaceuticals for hyperlipidemia: impact on insurance premiums. N Engl J Med. 2015;373(17):1591-1593.